Hanne Damgaard Jensen

Hanne Damgaard Jensen is an experienced pharmaceutical executive with a strong background in drug development and regulatory affairs. As the CEO and Founder of ROS Therapeutics since April 2018, Hanne leads initiatives to innovate treatments for children with juvenile arthritis through an oral methotrexate product. In addition, Hanne serves as Chief Development Officer at Curasight and has held various senior roles at companies such as AimVion A/S, Azanta A/S, Santaris Pharma, Genmab, Novo Nordisk, and IOLAB. Notable achievements include the successful registration of products in Denmark and the establishment of compassionate use programs for oncology treatments. Hanne holds an MBA from Copenhagen Business School and an M.Sc. in Pharmacy from Danmarks Farmaceutiske Universitet.